← Oncology Approval Tracker

FDA DECISION ·

Padcev

enfortumab vedotin-ejfv · Astellas Pharma

FDA approvalNew or expanded indicationUrothelial carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin and had received at least one prior treatment line.

LAMPGEN ANALYSIS

Why it matters

The same-day label expansion adds a population defined by cisplatin ineligibility and prior therapy.

What research teams should watch

Record the clinical rationale for cisplatin ineligibility separately from previous platinum exposure.

PRIMARY RECORDS

Sources